Fluorofenidone Attenuates Diabetic Nephropathy and Kidney Fibrosis in db/db Mice

Potential New Therapeutic Agents for Diabetic Kidney Disease

(2010) Faruk Turgut et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Isoliquiritigenin Entails Blockade of TGF-β1-SMAD Signaling for Retarding High Glucose-Induced Mesangial Matrix Accumulation

(2010) Jing Li et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Therapeutic Intervention in Diabetic Nephropathy

(2009) Claire E. Hills et al.   AMERICAN JOURNAL OF NEPHROLOGY

High ambient glucose induces angiotensin-independent AT-1 receptor activation, leading to increases in proliferation and extracellular matrix accumulation in MES-13 mesangial cells

(2009) Naohiro Yano et al.   BIOCHEMICAL JOURNAL

Role of Growth Factors in Diabetic Kidney Disease

(2009) F. Chiarelli et al.   HORMONE AND METABOLIC RESEARCH

Pirfenidone Is Renoprotective in Diabetic Kidney Disease

(2009) S. P. RamachandraRao et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy

(2009) U. F. Mehdi et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Fluorofenidone attenuates collagen I and transforming growth factor-β1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells

(2009) ZHANG-ZHE PENG et al.   NEPHROLOGY

Progress in diabetes research in China

(2009) Guang NING et al.   Journal of Diabetes

Diabetic Nephropathy: Mechanisms of Renal Disease Progression

(2008) Yashpal S. Kanwar et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis

(2007) M. Petersen et al.   KIDNEY INTERNATIONAL